In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

The S&P 500 rebounded in May, but some stocks crashed on company-specific concerns. While one healthcare giant withdrew its ...

The stock’s decline was notably more severe than that of its partner, Sanofi (NASDAQ:SNY), which experienced a 6% drop. Bernstein SocGen analysts highlighted concerns about Regeneron’s ability ...

could shift investor focus away from concerns over the erosion of Eylea, another of Regeneron’s products. This shift could potentially lead to an appreciation in stock value, aligning it more ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $600.0 for Regeneron Pharmaceuticals over the last 3 months ...

could shift investor focus away from concerns over the erosion of Eylea, another of Regeneron’s products. This shift could potentially lead to an appreciation in stock value, aligning it more closely ...

They encourage investors to remain buyers of Regeneron’s stock, anticipating a meaningful appreciation in value as the market shifts its focus towards the company’s broader portfolio and future growth ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on trade and ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

Regeneron's stock was up just over 1%. The steep discount on the once highly valued testing firm puts an end to concerns about the ... testing model still holds value. That has been evidenced ...